Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Amarin Pharma, Inc. et al v. Coromega Health, Inc.
Case Number:
3:18-cv-02481
Court:
Nature of Suit:
Judge:
Firms
-
May 06, 2019
Amarin Says Attys 'On Speed Dial' After Ending Omega-3 Suits
Amarin Pharma Inc. on Monday announced legal settlements with two dietary supplement sellers that allegedly hijacked results from the drugmaker's high-profile study of omega-3 fatty acids, adding that it has attorneys "on speed dial" to sue other supplement makers if needed.
-
October 30, 2018
Amarin Says Supplement Cos. Can't Tout Its Omega-3 Trial
Amarin Pharma Inc. has accused two supplement makers in California federal court of undercutting the reputation of its U.S. Food and Drug Administration-approved medication Vascepa by relying on its clinical trial to prove that their own omega-3 products have cardiovascular benefits.